BJOG : an international journal of obstetrics and gynaecology
-
Randomized Controlled Trial Multicenter Study
Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN).
To compare the recurrence rates after complete response to topical treatment with either cidofovir or imiquimod for vulval intraepithelial neoplasia (VIN) 3. ⋯ Long-term data indicates a trend towards response being maintained for longer following treatment with cidofovir than with imiquimod, with similar low rates of adverse events for each drug. Adverse event rates indicated acceptable safety of both drugs TWEETABLE ABSTRACT: Long-term follow up in the RT3VIN trial suggests cidofovir may maintain response for longer than imiquimod.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women; a multicentre randomised placebo controlled trial.
To evaluate the reduction of pain by misoprostol compared with placebo prior to hysteroscopy in postmenopausal and premenopausal nulliparous women. ⋯ RCT: misoprostol versus placebo prior to hysteroscopy in 149 women significantly reduces some pain parameters.
-
Randomized Controlled Trial Multicenter Study
Preoperative effects of mifepristone for dilation and evacuation after 19 weeks of gestation: a randomised controlled trial.
-
Randomized Controlled Trial Comparative Study
Application of dexmedetomidine-remifentanil in high-intensity ultrasound ablation of uterine fibroids: a randomised study.
To compare the effects of dexmedetomidine-remifentanil with the traditional analgesia and sedation regimen midazolam-remifentanil during HIFU treatment of uterine fibroids. ⋯ Dexmedetomidine-remifentanil is associated with more stable sedation in patients, more efficient HIFU treatment and higher degree of patient comfort than is midazolam-remifentanil.
-
Randomized Controlled Trial
Enhancing ablation effects of a microbubble contrast agent on high-intensity focused ultrasound: an experimental and clinical study.
To investigate the relationship between SonoVue ablation enhancement effects on high-intensity focused ultrasound (HIFU) and the concentration of SonoVue and timing of HIFU. ⋯ SonoVue, a microbubble contrast agent, enhanced the ablation effects of HIFU treatment; the optimal time to begin HIFU sonication appears to be 1 minute after the administration of SonoVue.